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Abstract 
 
The disabling nature and costly impact of mental disorders, such as schizophrenia, can cause 
significant burden to both person and society. It is also indicated that the negative outcomes 
associated with psychosis may, in part, be due to the delayed detection and initiation of 
treatment. Preventative interventions in several arenas of medicine have advanced; however 
have only come to the fore in psychiatry in the last two decades. It was long-known that a 
preclinical phase preceded psychosis, now commonly termed as ultra high-risk (UHR) status. 
The advent of specialized early intervention services provided the cornerstone in taking a 
preventative and timely endeavor to maximize the chance of positive outcomes in psychosis. 
Despite the potential, the current state of the UHR concept lacks consensus in how at-risk 
individuals should be approached. This chapter aims to provide an overview of how 
preventative medicine can intersect with psychiatry by focusing on the psychosis high risk 
state. It describes the current criteria and screening procedures used to prospectively detect 
UHR individuals, as well as discussing the validity of these tools. Whilst advocating the 
benefits of focused interventions, this chapter also recognizes current challenges and the 
controversy that leaves the psychosis high risk state on fertile ground for wavering opinions. 
The chapter concludes with an exploration and discussion that proposes an improved  
conceptualization of the high risk state and how this can direct intervention, as well as 
suggesting future lines of research in this area.   
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Background 
 
Over the past couple of decades, preventative approaches in several medical fields have 
flourished and developed. In fact, historically in the last century in the industrialized 
countries, an epidemiological shift occurred from infectious to chronic diseases, hence from 
premature death to years lived with disability, as the main concern for health-related 
professions[1].	   As a consequence, the major goal of health policies became to preserve 
individuals in full health for the standard life expectancy, by means of preventative 
interventions.  
The Institute of Medicine defines three categories of preventative interventions, according to 
their target population’s level of risk:  
1. Universal preventive interventions target “the general population that has not been 
identified on the basis of individual risk” [2], hence they are usually implemented in 
schools, whole communities, or workplaces. 
2. Selective preventive interventions target “population sub-groups with a significantly 
higher risk than the wider population” [2]. They aim at preventing the emergence of a 
given disorder, by addressing biological, psychological, or social risk factors known 
to be more prominent among high-risk groups. 
3. Indicated preventive interventions target “high-risk individuals who are identified as 
having minimal but detectable signs or symptoms foreshadowing a given disorder” 
[2]. Interventions focus on the immediate risk and protective factors present in the 
environments surrounding individuals. 
Until two decades ago, the field of psychiatry had remained excluded from preventative 
approaches, particularly for interventions in schizophrenia. Psychiatric interventions were 
confined to address the acute phase of illness where positive and negative symptoms were 
florid, or the more chronic stage where functional decline was evident [3]. 
However over the past two decades, availability of psychometric instruments to prospectively 
identify subjects at high clinical risk for psychosis has triggered the development of 
preventative diagnoses and interventions in psychosis. 
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Clinical relevance and impact of delayed treatment 
 
Recent surveys into the morbidity burden in Europe reported disorders of the brain and 
mental disorders as contributing 26.6% of the total cause burden (30.1% in females and 
23.4% in males) (Fig.1), as measured by DALYs (Disability-Adjusted Life Years), which is 
the sum of YLLs (Years of Life Lost due to premature mortality) and YLDs (Years Lived 
with Disability)[4]. Mental disorders are extremely disabling and costly, as indicated by the 
amount of work loss days, loss of work productivity, early retirement, and quality of life. 
Moreover, compared to other chronic diseases, they exert their load mainly on young adult 
men from 15-39 years of age, who represent the most economically active fraction of the 
population[5] (Fig.1). Among disorders of the brain, schizophrenia ranks as the 8th cause of 
DALYs in Europe[4]. Worldwide, a disturbingly high gap exists between the prevalence of 
those with mental disorders and those who receive treatment, particularly in low middle-
income countries. It emerged that only about 35% to 50% of all subjects with mental 
disorders receive any professional help for their health[6]. Moreover, even once provided, 
there is often a notable treatment delay. A recent prospective study has estimated that the 
duration of untreated psychosis (DUP), defined as the time of onset of the first psychotic 
symptom to the initiation of adequate treatment[7], has a median value of 25.7 weeks, 
ranging from 2 weeks up to 182 weeks[8]. A significant correlation has been consistently 
observed between long lapses of DUP and outcome [9]. A long DUP has been found to be 
associated with more severe positive and negative symptoms [10-12], longer length of first 
hospitalization[13], poorer  remission status and  higher  risk of relapse and 
rehospitalisation[8, 11, 13, 14]. Such negative outcomes can lead to further consequences, 
such as increased burden and expressed emotion in the family[15], reduced compliance to 
treatment[16, 17], lower treatment response rates [18-22], increased risk of depression, 
suicide and self-harming behaviour [23-25], higher risk of violence, aggression and 
delinquent behaviour [26-28] and eventually greater impairment in general functioning, 
social functioning and quality of life[11, 14, 29, 30].  
Early detection and intervention services serve as potential means of the timely recognition 
and initiation of treatment for psychosis. Indeed evidence has shown that the introduction of 
such services is consistently followed by a reduction in the DUP, an increase in the 
proportion of patients treated within 6 months of onset and a significant improvement in short 
term clinical outcome, in terms of rates of hospitalization and compulsory admission[31, 32].  
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Delaying treatment to the point where acute and disturbing psychotic symptoms have 
manifested may potentially place the individual at a vulnerable stage along the continuum of 
schizophrenia, which is a slippery slope down towards the classically described deterioration 
syndrome [30]. 
 
*** Figure 1 about here *** 
 
Detectable preclinical phase 
 
The existence of early symptoms predating the onset of schizophrenia has been long 
recognized[33, 34] and were initially named “prodromal” in 1932 by Mayer-Gross[35]. The 
research field regarding psychotic antecedents was launched in 1989 with the work of Huber 
and Gross[36], who investigated the chance of those presenting with basic disturbances 
would transition to full-blown psychosis. Later, the ABC (Age, Begin, and Course) 
Schizophrenia Study, a representative study on a large group of patients of whom 232 
suffered from first-episode psychosis, provided more robust evidence that psychotic 
symptoms are already present before the first hospitalization for schizophrenia, on average 
for 1 year and up to 5 years in up to 73% of all patients[37-39]. Earliest signs of a mental 
disorder in the sense of prodromal symptoms had occurred an average 5-6 years before first 
hospitalization and 4-5 years before first psychotic symptoms [37-40] 
Despite the concept being widely known, the prodromal phase still lacked univocal definition 
until two decades ago. This was due to the difficulty in unambiguously marking whether or 
when an individual’s experience or behaviour has crossed the boundary from the eccentric or 
unusual into the psychotic. A further challenge was the blurred and pleiotropic nature of 
prodromal symptoms, which lay mainly in the domain of depressive mood, negative 
symptoms and functional impairment[41], rather than in that of the more dramatic positive 
psychotic symptoms, such as hallucinations and delusions[37, 42] (Fig.2). 
 
*** Figure 2 about here *** 
A reliable and accurate detection of the preclinical phase of schizophrenia requires adequate 
frameworks and instruments. Over the past two decades two major trains of research have 
been developed for and applied to young help-seeking individuals at specialized services. The 
former, which had been pioneered by the Melbourne group of the Personal Assessment and 
Crisis Evaluation (PACE) clinic[43, 44], gave rise to ultra-high risk (UHR)[45], clinical high-
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risk[46] or at-risk  mental state (ARMS) status[47]; the latter, based on the investigations of 
Klosterklotter et al. (1996), focused on basic symptoms (BS)[48]. 
The mentioned preliminary investigations have put forth the operationalized high risk (HR) 
diagnostic criteria below: 
• Attenuated Psychotic Symptoms (APS), which encompasses young people 
experiencing psychotic symptoms at sub-threshold intensity - not severe enough- or 
sub-threshold frequency -not occurring often enough to meet a diagnosis of 
schizophrenia. 
• Brief Limited Intermittent Psychotic Symptoms (BLIPS), defined as the presence of a 
psychotic episode of less than seven days which remit spontaneously with no 
medication or hospitalization. 
• Genetic Risk and Deterioration Syndrome (GRD), which includes young people at- 
risk of psychosis due to the combination of a trait vulnerability (i.e. family history of 
psychosis in a first degree relative or schizotypal personality disorder in the identified 
patient) and a significant deterioration in mental state and/or functioning.  
• Cognitive perceptive Basic Symptoms (BS), which identifies at-risk persons on the 
basis of subtle cognitive and perceptive alterations. Basic symptoms are subjective 
disturbances of different domains, including perception, thought processing, language 
and attention that are distinct from classical psychotic symptoms.  They are 
independent of abnormal thought content and reality testing, and insight into the 
symptoms’ psychopathologic nature is intact[49]. 
The APS criterion is the most prevalent within the ARMS. For example, it resulted in the 
most represented diagnostic group (70%) followed by APS + GRD (11%) and BLIPS (9%) in 
a ten-year survey (2001-2011) of the Outreach and support in South London (OASIS) 
service[50]. 
 
The screening procedures 
 
The assessment of young help-seeking subjects is performed via different semi-structured 
psychometric interviews, which operationalize the above-mentioned criteria. Similar, yet not 
exactly alike, instruments have been developed and prospectively validated for the 
UHR/CHR/ARMS state.  The first psychometric instrument, the Comprehensive Assessment 
of At-Risk Mental State (CAARMS), was proposed by Yung et al.[51]	  on the basis of the 
work of the Melbourne group of the Personal Assessment and Crisis Evaluation (PACE)[52],	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whose goal was to determine the reliability of the prodromal symptoms in first-episode 
patients.  
In the following years, three further semi-structured interviews were developed; the 
Structured Interview for Prodromal Symptoms (SIPS) (including the companion Scale Of 
Prodromal Symptoms, SOPS)[53]; the Early Recognition Inventory for the Retrospective 
Assessment of the Onset of Schizophrenia (ERIraos)[54]; and the Basel Screening Instrument 
for Psychosis (BSIP)[55]– and a self-rating Prodromal screening Questionnaire (PQ) has 
been developed and validated[56]. 
Regarding basic symptoms, they were originally assessed using the Bonn Scale for the 
Assessment of Basic Symptoms (BSABS)[57]	   and, more recently, the Schizophrenia 
Proneness Instrument, Adult version (SPI-A) [58].	   Besides a variety of subjective 
disturbances in affect, drive, stress tolerance, and body perception, these instruments focus on 
self-perceived cognitive and perceptual changes, ultimately clustered in 2 subsets relating to 
the COPER criteria (10 cognitive-perceptive BS) and the COGDIS criteria (the 9 cognitive 
BS that are the most predictive of later psychosis)(compare chapter by Schultze-Lutter in this 
volume). 
 
Positive predictive value 
 
Although summary results of the diagnostic accuracy of the UHR criteria are still lacking, 
data from different research groups carrying out psychosis preventative interventions are 
available and informative. A recent retrospective evaluation in patients with first-episode 
psychosis found the UHR construct to be highly sensitive. Up to 98.4% of patients reported 
prodromal symptoms predating the onset of full-blown psychosis[59]. 
As for positive predictive value, a meta-analysis calculated that on average 29.2% of subjects 
in a HR state transitioned to a full psychotic episode within 24 months. The transition risk 
progressively increased over time, ranging from 17.7% at 6 months up to a peak of 35.8% at 
36 months[60].  
The transition risk following a UHR diagnosis was significantly higher in subjects meeting 
the criteria compared to help-seeking subjects who screened as negative (30% vs 2%)[61]. 
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Epidemiology of UHR symptoms  
 
In order to have the “attenuated psychotic syndrome” criteria, currently listed in Section III of 
the DSM-5 [62], included in the DSM-5 main section, its prevalence and clinical significance 
in the general population need to be elucidated. The epidemiological validity of the UHR 
state remains a major issue. In fact, the psychosis high-risk criteria achieved validity only in 
help-seeking subjects. Furthermore, the UHR syndrome did not show epidemiological 
stability overtime, since a decline in transition rates has been observed over recent years. 
Different explanations were proposed for the reported trend. Firstly, local communities are 
becoming more familiar with the HR state, thus referring younger clients at earlier and less 
severe stages of the prodrome, which could require longer follow-up periods to transition. 
Secondly, more recent studies recruit subjects who are also offered active treatments and this 
clinical engagement can potentially impact on the transition risk [60]. In studies conducted in 
non-help seeking community-based adolescents, UHR criteria, as operationalized by the 
aforementioned psychometric instruments, were met by 2% to 8% of the participants, without 
applying the criterion of a 30% drop in functioning in the last year. The latter would decrease 
the prevalence to 0-0.9% [63, 64]. Similarly, a study found that 0.3% of young adults from 
the general population (age range 16-40 years) met current “attenuated psychosis syndrome” 
criteria [62]. However, having excluded the criterion for an onset or worsening of the APS 
within the past year led to a prevalence of 2.6%, thus avoing to dismiss 2.3% of subjects who 
experienced and were distressed by APS [65]. It has been proposed that since the APS is to 
be considered a self-contained, rather than an at-risk syndrome, the onset/worsening criteria 
originally proposed to capture the progression towards frank psychosis would be better 
revised to differentiate from schizotypal traits (i.e., to “not always having been present in its 
current severity”) [65]. In the same way, Psychotic-Like Experiences (PLEs) have proven to 
have very high sensitivity but far too low specificity. Delusion- or hallucination-like 
experiences are referred with a prevalence rate of 5% and an incidence rate of 3% in the 
general population [66], but in most cases they are transitory, not associated with any distress 
and not related to any actual transition risk toward psychosis[63, 65-69].  
The epidemiological studies conducted in general population are affected by several 
limitations. Telephone interviews are generally preferred to face-to-face interviews, because 
of their assumed larger response rate. However, they may introduce some selection bias given 
to unequally distributed availability of telephone numbers or language skill exclusion 
criterion. On the other hand, face-to-face interviews may lead to ascertainment bias, as 
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persons with family history might be more willing to participate, thus enriching the rates of 
the condition under study. Besides these caveats, future studies in the general population 
should compare the prevalence rates using different time and functioning deficit criteria in 
order to identify an optimal threshold to reliably distinguish between at-risk and non-at-risk 
persons [63-65].   
 
Focused interventions 
 
The care provided by early intervention services has been shown to reduce the DUP as well 
as improve short term clinical outcomes, such as the rates of hospitalization and compulsory 
admission[32].  
Although the implementation of early intervention services leads to a great economic burden 
compared to the costs of standard care in the first years, the apparent economic loss due to 
direct costs (diagnostic measures, treatment and care)[4] is largely compensated in the 
following years by a substantial reduction of the disproportionally high indirect cost burden 
(disability, quality of life) of psychosis. A meta-analysis has further confirmed the cost 
effectiveness of early detection and early intervention services[70]. 
Treatment guidelines proposed by different international organizations have been depicted in 
Table 1. A recent meta-analysis of 11 trials including 1246 participants showed that focused 
interventions can halve the risk of psychosis onset (RR=0.5) [71]. Treatments that have 
demonstrated efficacy include cognitive therapy[72], cognitive behavioural therapy 
(CBT)[73], antipsychotic drugs[74], combined psychological and pharmacological 
interventions (risperidone plus CBT)[75], nutritional interventions (omega-3 fatty acids)[76], 
and integrated psychological interventions (cognitive therapy, social skills training, 
psychoeducation for family, and cognitive remediation)[77]. However, the evidence collected 
from these trials is not to be considered conclusive but rather preliminary[71].	   Moreover, 
since the treatment is biased toward attenuated positive psychotic symptoms, it is scarcely 
tailored to negative symptoms and early deficits, which are among the main complaints of 
HR subjects and best correlate with loss of functioning and worse prognosis[78,	   79].	  Until 
better alternative interventions specifically targeting this medical condition are identified, the 
safest approach is recommended with careful consideration of the risk-benefit ratio of 
treatment.  
 
*** Table 1 about here *** 
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Comparison with other preventative approaches in somatic medicine 
 
The goodness of psychosis prevention can be expressed through statistical indexes and so 
directly compared with other established preventative approaches in somatic medicine. 
Preventative cognitive behavioural therapies in psychosis are associated with a 0.5 RRR 
(Relative Risk Reduction) and a NNT (number of subjects who need to be treated to prevent 
one additional bad outcome) of 14[80, 81]. These values are comparable to those calculated 
for metformin in the prevention of diabetes (NNT = 14)[82] and even superior to those found 
for statins in preventing cardiovascular serious events (NNT = 25), although these were 
computed in the longer term[83] (Tab.2). 
 
*** Table 2 about here *** 
 
 
 
Risk syndrome or mental disorder 
 
The preparation of the fifth revision of the Diagnostic and Statistical Manual for Mental 
Disorders (DSM-5) raised a debate about the inclusion of a risk syndrome for psychosis, 
which is alike the diagnosis of each grade of cervical dysplasia that are included in ICD-10. 
The main objections to its inclusion pointed towards the potential stigma associated with a 
diagnosis of schizophrenia as well as the over-treatment of subjects falsely classified as 
positive, that is, who will never go on to develop psychosis. Indeed, UHR individuals, by 
definition, already experience changes in thinking, perception, affect, and behaviour, as well 
as significant decline in psychosocial functioning and in quality of life. The formal evidence 
that HR subjects are “probably at risk but certainly ill”[84]	   derives from a meta-analysis, 
which demonstrated that HR subjects are as impaired as psychotic patients in quality of life 
and global functioning at a level that is lower than healthy controls[85]. Moreover, the level 
of global functioning seems to predict later conversion to psychosis[85]. Therefore, it has 
been proposed that the currently defined “at-risk state” be conceptualized as an independent 
disorder in its own right[86]. Consequently, the emphasis would move from prediction and 
prevention to symptom improvement.  
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Nonetheless, the observations above only provide support for the conceptual validity of the 
HR state, i.e. correctly distinguishing between disorder and normality. There is still much to 
be done in order to fulfill construct validity, i.e. correctly distinguishing between the actual 
and other disorders, which will be needed in order to bring a new APS syndrome in the DSM-
5.1 main text[87]. In particular, the syndrome should additionally demonstrate biological 
markers, such as laboratory and instrumental correlates; epidemiological validity and socio-
demographic consistency; and diagnostic stability, in terms of delineation of one disorder 
from another and predictability of the course of illness[88]. With regards to diagnostic 
stability, it should be noted that the UHR is usually an aggregate of comorbid disorders. 
Since psychopathological boundaries are not so well-defined, patients at-risk for psychosis 
may fulfill diagnostic criteria for depression, anxiety, substance abuse, personality disorders, 
and developmental disorders[73].	  More importantly, the construct holds the characteristic of 
pluripotency, in terms of heterogeneity of longitudinal outcomes. Among non-transitioning 
patients, about 46% appear to  remit [89], some persist in ongoing attenuated psychotic 
symptoms, and others progress to other disorders, mainly bipolar disorder, depression and 
anxiety[73]. A meta-analysis performed on a database of 2182 HR subjects revealed that the 
available HR criteria, in particular the BS criteria, are strongly biased toward the 
identification of early prodromal phases of schizophrenic psychosis (SP) (73%) rather than 
affective psychosis (AP) (11%)[90]. In conclusion, the pluripotent model of the psychosis 
high-risk state encompasses different types of cases with attenuated psychotic experiences, 
each associated with a different evolution. Some of the baseline psychopathology may reflect 
the emergence of an underlying core psychotic process prodromal for schizophrenia or 
another psychotic disorder (true prodromal); some may be associated with a non-psychotic 
clinical condition such as depression (clinical noise); and some may represent normal 
variation in the general population (incidental psychosis). 
 
Conclusions and future directions 
 
The past two decades have seen a great interest and rise in the importance of the prodromal 
phase of psychosis. This has been achieved by shifting the traditional negative views of 
schizophrenia as a disorder with an unpredictable onset and that may be progressive in nature 
with disabling outcomes (dementia praecox) to a disorder that can be delayed, if not 
prevented, through recognition of those at imminent risk. In this chapter, the evidences 
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advocating this category as the possible target of focused interventions have been 
summarized. Moreover, its role as a new diagnosis in its own right in the DSM 5 has been 
discussed and a shift of the focus from an uncertain future outcome to current 
psychopathology and needs has been proposed. However, further research is warranted, since 
many questions remain unanswered. First, it is not clear whether the validity of UHR as used 
by specialized services can be generalized to general psychiatry/psychology and primary 
care. It has been argued that the diagnosis of APS in general practice may lead to excessive 
therapeutics doing more harm than good as well as adding a significant burden, in terms of 
stigma, to persons experiencing attenuated psychotic symptoms. However, greater attention 
should be paid to impairments in self, autonomy, personhood, and emotional regulation that 
people meeting criteria for APS already present. Second, because APS is a broad-based 
concept, interventions aimed at secondary prevention of psychosis could be tailored on which 
psychotic disorder vulnerability is present (i.e., schizophrenia spectrum disorder, bipolar 
disorder, or mood disorder). Third, reliable markers are needed in order to stratify the HR 
population according to the prediction of outcome; thus, broader and better validated 
longitudinal studies would be recommended, comparing HR subjects to healthy individuals as 
well as to people suffering from comorbid diagnoses.  Finally, effective interventions should 
be developed and tested that address the specific needs of at-risk people. Therapeutic 
discovery should be more focused on functional outcomes or methods for enhancing 
resiliency or for reducing risk factors such as stress, with less emphasis placed on psychosis 
prevention. To date, the treatments that have been proven to be effective in frank psychosis 
have largely focused on positive symptoms, however there is increasing evidence to suggest 
that negative symptoms as well as cognitive and social functioning meaningfully restrict the 
prognosis. For example, therapies aimed at ameliorating emotion recognition or exerting a 
neuroprotective effect may have potential benefits. It is hoped that in the future more 
knowledge be acquired at developmental stages preceding APS, where prevention strategies 
have an earlier focus on reducing movement into vulnerability  and, in the vulnerable, 
enhancing resiliency  [86]. APS serves as a platform for future research and clinical work. 
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Table 1. Treatment guidelines for the psychosis high-risk state 
Organization Recommendations 
American Psychiatric Association “Careful assessment and frequent monitoring” 
Canadian Psychiatric Association “Should be offered monitoring” 
“May be offered supportive therapy and 
symptomatic treatment” 
International Early Psychosis Association “Antipsychotic medications not usually 
indicated” unless “rapid deterioration” or “sever 
suicidal risk and treatment of depression has 
proven ineffective” or “aggression and hostility 
are increasing and pose a risk to others” 
“If antipsychotics are considered...may be 
continued” up to 2 years, and then “attempt to 
withdraw the medication should be made” 
Royal Australian and New Zealand College of 
Psychiatrists 
“Antipsychotic medication not normally 
prescribed” unless “symptoms are directly 
associated with risk of self-harm or aggression” 
Italian National Institute of Health “Use of antipsychotic medication” is “doubtful”; 
behavioural cognitive treatment is recommended 
German Association for Psychiatry, 
Psychotherapy, and Neurology  
“Continuous care and follow-up. If relevant 
symptoms reaching disorder level occur, CBT 
and sociotherapy should be offered. If psychotic 
symptoms emerge, antipsychotics should be 
offered” 
CBT, cognitive behavioural therapy 
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Table 2.  Psychosis prevention compared to common preventative approaches in clinical 
medicine 
At-risk 
population 
Outcome Transition 
risk % 
Risk-
focused 
treatment 
Risk 
placebo 
RRR ARR NNT 
Psychosis 
high-risk state 
Psychosis 17%-28%  
(1 
year)[91] 
CBT 7% (1 
year) 
[91] 
Supportive 
counselling 
14% (1 
year) [91] 
0.5 (1 
year) 
[91] 
0.07 
(1 
year) 
[91] 
14 (1 
year) 
[91] 
CBT + 
risperidone 
17% (1 
year) [91] 
CBT + 
placebo 
28% (1 
year) [91] 
0.39 
(1 
year) 
[91] 
0.11 
(1 
year) 
[91] 
9 (1 
year) 
[91] 
Omega 3 
FA 7.2% (1 
year) [91] 
Supportive 
counselling 
40% (1 
year) [91] 
0.82 
(1 
year) 
[91] 
0.33 
(1 
year) 
[91] 
3 (1 
year) 
[91] 
Prediabetes  Diabetes 5%-19% (1 
year) [92] 
Metformin 
21.7% (3 
years) [82] 
Placebo 
28.9% (3 
years) [82] 
0.25 
(3 
years) 
[92] 
0.07 
(3 
years) 
[82] 
14 (3 
years) 
[82] 
Lifestyles 
14.4% (3 
years) [82] 
Placebo 
28.9% (3 
years) [82] 
0.5 (3 
years) 
[92] 
0.14 
(3 
years) 
[82] 
7 (3 
years) 
[82] 
Cardiovascular 
high-risk 
patientsa 
Serious 
cardiovascular 
eventsb 
1.5%  [93] Antiplatelet 
therapy 
9.9% (2 
years) [83] 
Placebo 
14% (2 
years) [83] 
0.35 
(2 
years) 
[83] 
0.04 
(2 
years) 
[83] 
25 (2 
years) 
[83] 
a High-risk patients defined as subjects with stable angina 
b Serious cardiovascular events defined as nonfatal myocardial infarction, nonfatal stroke, or 
death from a vascular cause 
CBT, cognitive behavioural therapy; NS, not significant; FA, fatty acids; RRR, relative risk 
reduction; ARR, absolute risk reduction; NNT, numbers needed to treat.  
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Figure 1. Percentage of global Disability-Adjusted Life Years by age, sex, and cause in 2010 
worldwide. Distribution of DALYs for male individuals (A) and female individuals (B) [5]. 
Morbidity burden of disorders of the brain and mental disorders in EU, for male (C) and 
female (D) individuals [4].  
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Figure 2. The early stages of schizophrenia from first sign of mental disorder to first 
admission (ABC first-episode sample N = 232; (108 men, 124 women)) [38]  
 
